Structure Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
GPCR$21.41+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended June 30, 2024, the following officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or modified a “Rule 10b5-1 trading arrangement” (as such term is defined in Item 408(a) of Regulation S-K).
| | ||||||
|---|---|---|---|---|---|---|
| · · · Type of Trading Arrangement · · | ||||||
| Name and Position | Action | Date | Rule 10b5-1* | Non-Rule 10b5-1** | Total ADSs to be Sold | Expiration Date |
| Mark Bach, M.D., Ph.D., Chief Medical Officer | Adoption | June 10, 2024 | X | | 24,000 | February 15, 2025 |
| Xichen Lin, Ph.D., Chief Scientific Officer | Modification | June 14, 2024 | X | | 24,000 | November 15, 2024 |
| | | | | | | |
| * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | ||||||
| ** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act. | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.